COX-2 Haplotypes and Esophageal Adenocarcinoma

Data suggest that carriers of the CA haplotype are at higher risk for esophageal adenocarcinoma than are noncarriers.

Local expression of cyclooxygenase (COX)-2 in the esophageal mucosa increases as reflux esophagitis and Barrett esophagus progress to esophageal adenocarcinoma (EAC). This increased expression and its associated enzymatic activity are linked to particular COX-2 haplotypes, one of which — the CA haplotype — is observed more commonly in patients with EAC than in patients with other gastroesophageal reflux diseases. Researchers performed a genetic association study to determine the extent to which COX-2 haplotypes influence risk for EAC.

DNA samples were obtained from 635 white patients who underwent endoscopy for reflux-related complaints at any of three Dutch medical centers between November 2002 and February 2005. EAC was diagnosed in 140 of…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors